These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11914932)

  • 1. NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.
    Gansauge F; Ramadani M; Pressmar J; Gansauge S; Muehling B; Stecker K; Cammerer G; Leder G; Beger HG
    Langenbecks Arch Surg; 2002 Mar; 386(8):570-4. PubMed ID: 11914932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer.
    Gansauge F; Ramadani M; Schwarz M; Beger HG; Lotspeich E; Poch B
    Hepatogastroenterology; 2007; 54(75):917-20. PubMed ID: 17591092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
    Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
    Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
    Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
    J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
    Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
    J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
    Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
    Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
    Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
    Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
    Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Aitini E; Marangolo M
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):51-7. PubMed ID: 16767907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
    Wang X; Ni Q; Jin M; Li Z; Wu Y; Zhao Y; Feng F
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):404-7. PubMed ID: 12408777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
    Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
    Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
    Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
    J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
    Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
    Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
    Alberts SR; Foster NR; Morton RF; Kugler J; Schaefer P; Wiesenfeld M; Fitch TR; Steen P; Kim GP; Gill S
    Ann Oncol; 2005 Oct; 16(10):1654-61. PubMed ID: 16085692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Hamm J; Dancey J; Eisenberg PD; Dagenais M; Fields A; Hagan K; Greenberg B; Colwell B; Zee B; Tu D; Ottaway J; Humphrey R; Seymour L;
    J Clin Oncol; 2003 Sep; 21(17):3296-302. PubMed ID: 12947065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.